
Fully Human Antibodies, Acceleration of Discovery & Development
Mission

Individual Project Design, Fee for Service or Milestone-based
Contract Research, R&D Services

Partnered R&D, Collaborations, Licensing
Pipeline & Partnering
Bridging the gap from target to lead
The success of next generation antibody drug development relies on comprehensive discovery technologies and strategies.
YUMAB bridges the gap between research innovation and novel therapies. Our advanced discovery platform provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate.
From target discovery to fully characterized lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.
and watch our coporate image video:
YUMAB AND INSCREENEX IN JOINT FUNDING PROJECT
July 19, 2023
YUMAB announces its collaboration with InSCREENeX under the “exPDITE” funding project. The goal of the collaboration is to enable improved drug development for the individual treatment of patients with pancreatic cancer.
YUMAB offers contract research, technologies and R&D services for the discovery and development of fully human, therapeutic antibodies.
YUMAB also provides partnering and collaboration strategies to provide access to our technologies and expertise for academic spin-offs and start-up companies without the burden of technology access fees.
Phone: (+49) 531-481170-0
Email: info@yumab.com
1100 South Tower
225 Peachtree Street NE
Atlanta, GA 30303 – USA
Phone: (+49) 531 481170-0
Email: info@yumab.com